RxDoctor Payments Data

Deepti Gupta, MD

Internal Medicine · Port Jefferson Station, NYNPI 1619936069

Payments from drug & device makers

$3,414in general payments, 2019–2025

Across 158 payments — averaging $21.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$684
  • Pfizer$531
  • Lilly USA, LLC$465
  • AstraZeneca$366
  • Novo Nordisk$277
  • AbbVie$235
  • plus $857 from 18 others

What the payments were for

  • Food & beverage$3,403100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,414 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$301,997
Medicare patients
458
Services billed
4,727

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide93$124,721
EliquisApixaban59$56,691
MounjaroTirzepatide35$46,405
JanuviaSitagliptin Phosphate21$21,349
JardianceEmpagliflozin11$19,070
FarxigaDapagliflozin Propanediol14$18,627
Breo ElliptaFluticasone/Vilanterol28$14,121
Combivent RespimatIpratropium/Albuterol Sulfate19$11,978
Praluent PenAlirocumab16$11,626
XareltoRivaroxaban15$8,284
Levothyroxine Sodium383$5,051
Epinephrine27$5,005
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate27$4,976
Nebivolol Hcl63$4,535
Atorvastatin Calcium443$4,053

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$277$124,72193 claims
PfizerEliquis$531$56,69159 claims
Lilly USA, LLCMounjaro$465$46,40535 claims
Boehringer IngelheimJardiance, Combivent Respimat$38$31,04830 claims
AstraZenecaFarxiga$366$18,62714 claims
GSKBreo Ellipta$94$14,12128 claims
Johnson & JohnsonXarelto$107$8,28415 claims
AbbVieSynthroid$235$2,78052 claims
Almatica Pharma LLCSertraline Hcl$13$712110 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Port Jefferson Station

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →